| |
| |
|
| Insider
Information: |
Agarwal Shefali |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
10,490 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$39,862 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
10,490 |
|
|
| Total
Value |
$39,862 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -149.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Epizyme, Inc. |
EPZM |
See Remarks |
2022-08-12 |
0 |
2019-01-24 |
0 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
10,490 |
2021-06-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EPZM |
Epizyme, Inc. |
See Remarks |
– – – |
2022-08-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(286,539) |
0 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
– – – |
2022-08-09 |
4 |
D |
$1.39 |
$518,684 |
D/D |
(373,154) |
285,562 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
– – – |
2022-08-09 |
4 |
OE |
$1.39 |
$695,000 |
D/D |
500,000 |
658,716 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
10,490 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-07 |
4 |
S |
$21.89 |
$18,409 |
D/D |
(841) |
1,840 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-03 |
4/A |
S |
$0.00 |
$0 |
D/D |
(0) |
2,681 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.80 |
$18,400 |
D/D |
(807) |
1,874 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2022-02-28 |
4 |
A |
$1.27 |
$2,952 |
D/D |
2,331 |
158,716 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2022-02-07 |
4 |
AS |
$1.50 |
$1,587 |
D/D |
(1,058) |
156,385 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2022-02-02 |
4 |
AS |
$1.37 |
$3,615 |
D/D |
(2,639) |
157,443 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2022-01-26 |
4 |
AS |
$2.02 |
$5,902 |
D/D |
(2,922) |
160,082 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2021-12-06 |
4 |
AS |
$2.93 |
$5,215 |
D/D |
(1,780) |
163,004 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
See Remarks |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
59,166 |
163,507 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,681 |
2,681 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2021-02-04 |
4 |
AS |
$11.21 |
$10,862 |
D/D |
(969) |
104,341 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,583 |
105,310 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2021-01-25 |
4 |
AS |
$11.41 |
$32,770 |
D/D |
(2,872) |
75,727 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-12-03 |
4 |
AS |
$13.54 |
$34,148 |
D/D |
(2,522) |
76,089 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-06-26 |
4 |
AS |
$16.15 |
$29,151 |
D/D |
(1,805) |
78,611 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
80,416 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-03-25 |
4 |
AS |
$15.28 |
$18,993 |
D/D |
(1,243) |
71,991 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,575 |
73,234 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,856 |
71,659 |
0 |
- |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-01-27 |
4 |
AS |
$20.44 |
$53,757 |
D/D |
(2,630) |
58,803 |
0 |
% |
|
| EPZM |
Epizyme, Inc. |
Chief Medical Officer |
• – – |
2020-01-24 |
4 |
AS |
$24.64 |
$45,412 |
D/D |
(1,843) |
61,433 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
